New Two-Drug attack on childhood leukemia aims for deeper remission
NCT ID NCT06533748
Summary
This study is testing a new initial treatment for children and young adults (ages 1-18) newly diagnosed with B-cell leukemia or lymphoma. It combines two targeted drugs, inotuzumab and blinatumomab, to try to eliminate more cancer cells early in treatment. The main goal is to see if this approach leads to a deeper remission with fewer signs of leftover cancer compared to older treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint Francis Children's Hospital
RECRUITINGTulsa, Oklahoma, 74136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.